Palantir's UK NHS Contract Under Fire

It's April 5th.

Welcome to Durham News Today, powered by AI, I'm Corey with the story.

Palantir technology stock has surged over 90% in the past year, making it a top pick

amid global conflicts.

But now the company faces growing heat in the United Kingdom over its 330 million pound

national health service contract for a data, platform.

Critics question if a firm tied to defense and surveillance should handle public health

data, even as the system rolls out to over 100 trusts, with claims of boosting surgeries

and cutting wait times.

Earlier this week, Palantir's UK executive vice president defended their military AI tools

in a BBC interview, saying they speed up decisions, but leave policy and judgment to governments.

This comes right as UK lawmakers probe the NHS deal in a smaller contract with the financial

conduct authority for financial crime work.

Meanwhile, backlash is building from MPs, doctors and campaigners worried about vendor

lock-in, trust issues, and Palantir's defense links spilling into civilian sectors.

Supporters point to real benefits like fewer discharge delays, but the live contracts

make unwinding them tricky.

On the US side, the Pentagon just named Palantir's Maven AI System, an official program, locking

in long-term funding for battlefield data analysis, with human oversight.

Ties to Israel's defense ministry and past ice work have also sparked investor pull-outs,

like Norway's store brand fund, ditching its stake over ethical concerns.

Government revenue jumped 66% to $570 million last quarter, fueling growth, yet the same

ties create headline risks that could sway institutional money watch if UK ministers

pull the NHS break laws or scrutiny on Maven intensifies, balancing Palantir's momentum

against rising political heat.